1,2,3-Triazole derivatives: synthesis, docking, cytotoxicity analysis and in vivo antimalarial activity

• Published in: Chemico-biological interactions Vol. 350; p. 109688
• Main Authors: Valério Lopes, Fernanda, Fazza Stroppa, Pedro Henrique, Marinho, Juliane Aparecida, Reis Soares, Roberta, de Azevedo Alves, Lara, Capriles Goliatt, Priscila Vanessa Zabala, Abramo, Clarice, David da Silva, Adilson
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.12.2021
• Subjects: 1,2,3-Triazoles compounds; Antimalarial activity; Cytotoxicity evaluation; Molecular docking; Plasmodium berghei; Antimalarial activity; Plasmodium berghei; Cytotoxicity evaluation; Molecular docking; 1,2,3-Triazoles compounds
• ISSN: 0009-2797; 1872-7786
• DOI: 10.1016/j.cbi.2021.109688

Malaria remains one of the most important parasitic diseases in the world. The multidrug-resistant Plasmodium strains make the treatment currently available for malaria less effective. Therefore, the development of new drugs is necessary to overcome therapy resistance. Triazole derivatives exhibit several biological activities and provide a moiety that is promising from the biological perspective. Due to the structural similarity to NADH, it is believed that triazoles can bind to the active site of the Plasmodium lactate dehydrogenase (pLDH) enzyme. The present work evaluates the antimalarial activity of 1,2,3-triazole derivatives by in silico, in vitro, and in vivo studies. Preliminary in silico ADMET studies of the compounds demonstrated good pharmacokinetic properties. In silico docking analysis against LDH of Plasmodium berghei (PbLDH) showed that all compounds presented interactions with the catalytic residue in the active site and affinity similar to that presented by chloroquine; the most common antimalarial drug. Cytotoxicity and hemolysis by these derivatives were evaluated in vitro. The compounds 1, 2, 5, 8, and 9 proved to be non-cytotoxic in the performed tests. In vivo antimalarial activity was evaluated using mice infected with Plasmodium berghei NK65. The five compounds tested exhibited antimalarial activity until nine days post-infection. The compound 5 showed promising activities, with about 70% parasitemia suppression. Considering the in vitro and in vivo studies, we believe the compound 5 to be the most promising molecule for further studies in antimalarial chemotherapy. [Display omitted] •Synthesis and biological evaluation of new 1,2,3-triazole derivatives were reported.•The binding modes were studied by molecular docking.•Cytotoxicity and hemolysis of 1,2,3-triazole derivatives were evaluated.•All compounds tested showed antimalarial activity in vivo.•Compound 5 is the most promising for further studies in antimalarial chemotherapy.